Interesting that RES, LL, and the GLP-1 class are
Post# of 147877
As the “multi-hit hypothesis” holds, combining the therapeutic approaches of GLP-1 agonists with resmetirom seems like a promising strategy by targeting the multifaceted pathophysiology of MASH, which may lead to improved patient outcomes. While the “synergy” makes sense, it is still theoretical until proven in dedicated trials or, suboptimally, from data in real-world studies.